Athira Pharma (NASDAQ:ATHA) Rating Reiterated by JMP Securities

Athira Pharma (NASDAQ:ATHA)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a note issued to investors on Thursday, Benzinga reports. They currently have a $19.00 target price on the stock.

Athira Pharma Stock Up 14.0 %

ATHA stock traded up $0.31 during midday trading on Thursday, hitting $2.52. The company’s stock had a trading volume of 198,625 shares, compared to its average volume of 347,829. Athira Pharma has a 12 month low of $1.33 and a 12 month high of $4.30. The company has a 50 day moving average of $2.38 and a two-hundred day moving average of $2.51. The firm has a market capitalization of $96.59 million, a price-to-earnings ratio of -0.80 and a beta of 2.83.

Athira Pharma (NASDAQ:ATHA) last issued its earnings results on Monday, May 13th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.11. On average, analysts anticipate that Athira Pharma will post -2.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Athira Pharma

Several institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC bought a new position in shares of Athira Pharma during the 4th quarter valued at approximately $32,000. Mirador Capital Partners LP purchased a new position in shares of Athira Pharma in the 1st quarter worth $57,000. Forefront Analytics LLC increased its holdings in shares of Athira Pharma by 43.0% in the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock worth $72,000 after buying an additional 8,955 shares during the last quarter. Clarius Group LLC raised its position in shares of Athira Pharma by 35.8% during the 4th quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after buying an additional 14,124 shares in the last quarter. Finally, Laird Norton Trust Company LLC lifted its holdings in shares of Athira Pharma by 21.3% in the 3rd quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after acquiring an additional 31,400 shares during the last quarter. Hedge funds and other institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.